Non-Motor Fluctuations in Parkinson’s Disease (PD): Development and Validation of the Non-Motor Fluctuation Assessment Instrument (NoMoFA)
Objective: Validate and demonstrate reliability of the NoMoFA. Background: In patients with PD, sleep, mood, cognitive, autonomic and other non-motor symptoms (NMS) may fluctuate (NMF)…Early detection of Parkinson’s disease motor fluctuations with a wearable inertial sensor
Objective: To assess the utility of a wearable inertial sensor for detecting motor complications in Parkinson’s disease (PD) and its usability. Background: Identifying motor complications…Frequency of Wearing-Off Symptoms in Parkinson’s disease Fluctuators: An on/off evaluation
Objective: To determine if the frequency of wearing-off symptoms in Parkinson’s disease (PD) patients who report fluctuations differs from patients without fluctuations. Background: Wearing-off, the…Feasibility of a simplified, symptom-based electronic diary to improve evaluation of motor and non-motor complications in Parkinson’s disease
Objective: To determine the feasibility of the simplified and symptom-based electronic PD diary and compare with the standard paper diary. Background: Motor complications (MC) is…A randomized, placebo-controlled, double-blind clinical study in Japan of Opicapone treatment for Parkinson’s Disease -Comfort-PD Study part 1
Objective: To investigate efficacy and safety of two doses of Opicapone (OPC) compared to placebo administered once daily for 14 to 15 weeks to Japanese…Efficacy, Safety, and Tolerability of Supratherapeutic Doses of Apomorphine Sublingual Film for the Treatment of “OFF” Episodes in Patients With Parkinson’s Disease
Objective: To evaluate efficacy, safety, and tolerability of supratherapeutic doses of apomorphine sublingual film (APL-130277; APL) in patients with Parkinson’s disease (PD) and “OFF” episodes.…An open-label, 1-year extension clinical study in Japan of Opicapone treatment for Parkinson’s disease -Comfort-PD study part 2
Objective: To investigate the safety and efficacy of continuous treatment with 50 mg Opicapone (OPC) for 1 year after treatment with a placebo, 25 mg…Safety and Tolerability of Apomorphine Sublingual Film During Maintenance Treatment in Patients With Parkinson’s Disease and “OFF” Episodes: A Pooled Analysis
Objective: To examine safety and tolerability of apomorphine sublingual film (APL-130277; APL) during maintenance treatment using pooled data from 4 clinical studies in patients with…Patient insights into the burden of OFF-episodes in Parkinson’s disease: Qualitative Interviews
Objective: Identify symptoms and impacts associated with OFF-episodes (OEs). Background: OFF-episodes are commonly experienced in patients with Parkinson’s disease (PD). Qualitative research into patients’ experience…Diplopia and visual complaints in non-demented patients with Parkinson disease: a Japanese single center cross-sectional survey
Objective: To investigate the characterization of diplopia and visual complaints including minor forms of hallucinations (mHals) in non-demented patients with Parkinson disease (PD). Background: Double…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 24
- Next Page »